<DOC>
	<DOCNO>NCT03003520</DOCNO>
	<brief_summary>This Phase 2 , two-arm , open-label study design evaluate safety , clinical activity , predictive biomarkers pharmacokinetics/ pharmacodynamics durvalumab combination R-CHOP ( Arm A ) R2-CHOP ( Arm B ) , follow durvalumab consolidation therapy previously untreated subject high-risk DLBCL . Patients non-ABC subtype ( determine gene expression profile ) allocate Arm A patient ABC ( activate B-cell type ) subtype allocate Arm B . Approximately 120 patient may enrol assigned appropriate treatment arm dependent upon cell origin status . Induction treatment R-CHOP ( ± Lenalidomide ) last total 6 8 treatment cycle ( 21 day cycle ) , total time study treatment , include durvalumab consolidation , last 12 month .</brief_summary>
	<brief_title>A Study Durvalumab Combination With R-CHOP Lenalidomide Plus R-CHOP Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>This research study conduct patient previously untreated , high-risk Diffuse Large B-cell Lymphoma ( DLBCL ) . Patients high-risk DLBCL typically insufficient therapeutic outcome . Therefore , addition novel agent currently use induction therapy ( R-CHOP backbone ) rational approach improve therapeutic outcome disease set . Based pre-clinical clinical observation , hypothesize durvalumab activity DLBCL PD 1/PD L1 pathway involve pathophysiology DLBCL . In particular , addition durvalumab may significantly augment anti-tumor activity R-CHOP high-risk DLBCL subtypes . There different subtypes DLBCL distinguish Cell Origin ( ABC , GCB , unclassifiable ) . About third DLBCL ABC subtype patient worse outcome treat R-CHOP , lenalidomide plus R-CHOP ( R2-CHOP ) use patient ABC subtype . The safety durvalumab already explore . However , limited clinical experience durvalumab DLBCL , study divide two stage : - A Safety Run-in Stage evaluate safety treatment combination least 10 subject include two treatment arm total 20 subject - An Expansion Stage analyze clinical activity treatment combination 100 additional subject</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . CD20+Diffuse Large BCell Lymphoma . 2 . Ann Arbor stage 3 4 stage 2 bulky disease 3 . High highintermediate disease risk . 4 . No prior antilymphoma treatment . 5 . Subject willing able undergo biopsy . 6 . Investigator considers RCHOP immunochemotherapy appropriate . 7 . ECOG performance status 02 . 8 . Adequate hematology laboratory result ( absolute neutrophil count ≥ 1.5 x 10^9/L , platelet count ≥ 75 x 10^9/L , hemoglobin ≥ 10.0 g/dL ) . 9 . Adequate biochemistry laboratory result ( AST/SGOT ALT/SGPT ≤ 3.0 x upper limit normal ; bilirubin ≤ 2.0 mg/dL ; creatinine clearance ≥ 40 mL/min ) . 10 . Bidimensionally measurable disease ( &gt; 2.0 cm ) . 11 . Subject use effective contraception . 1 . Diagnosis lymphoma Diffuse Large BCell Lymphoma . 2 . Composite lymphoma transform lymphoma . 3 . Primary secondary Central Nervous System involvement lymphoma . 4 . Seropositive active viral infection hepatitis B virus , human immunodeficiency virus hepatitis C virus . 5 . History malignancy , unless diseasefree ≥ 5 year . 6 . Left ventricular ejection fraction &lt; 50 % . 7 . Peripheral neuropathy ≥ Grade 2 . 8 . Prior use lenalidomide , monoclonal antibody CTLA4 , PD1 , PDL1 . 9 . High risk develop thromboembolic event , unwilling take venous thromboembolism prophylaxis . 10 . Active prior document autoimmune inflammatory disorder within past 3 year . 11 . Current prior use immunosuppressive medication within 28 day start treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Diffuse-large B-Cell Lymphoma</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Anti-PD-L1 Antibody</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Immune Checkpoint</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone/Prednisolone</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>